Physician profile
Rita Burns
NPI 1376141135
$2,767.01
in general payments reported to CMS, 2019-2025
26 companies · $1,084 in 2025
The $1,084 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $149 · 2024: $1,534 · 2025: $1,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,767.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $470.64 | 2023-2025 | |
| Janssen Biotech, INC. | $422.57 | 2024-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $332.36 | 2024-2025 | Xifaxan, Plenvu |
| Ardelyx, INC. | $200.29 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $162.21 | 2023-2025 | Entyvio, Eohilia |
| Pfizer INC. | $139.70 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $128.32 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $126.45 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $114.26 | 2024-2025 | Vowst, Zenpep |
| Janssen Scientific Affairs, LLC | $94.28 | 2024 | Stelara |
| Qol Medical, LLC | $89.79 | 2024-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $69.41 | 2024 | |
| Ferring Pharmaceuticals INC. | $60.33 | 2023-2025 | Rebyota, Clenpiq |
| Madrigal Pharmaceuticals | $57.92 | 2024-2025 | Resmetirom, Rezdiffra |
| Celltrion USA INC. | $50.92 | 2025 | Vegzelma |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $33.02 | 2024 | Voquezna |
| Exact Sciences Corporation | $31.64 | 2025 | Cologuard Collection Kit |
| Csl Behring | $28.65 | 2023 | Kcentra |
| Intercept Pharmaceuticals, INC. | $22.78 | 2025 | |
| Galvanize Therapeutics, INC | $22.39 | 2024 | Aliya System |
| Braintree Laboratories, INC. | $21.85 | 2024 | Suflave |
| Genzyme Corporation | $20.43 | 2025 | |
| Blueprint Medicines Corporation | $19.60 | 2024 | Ayvakit |
| Eisai INC. | $16.94 | 2025 | |
| Celgene Corporation | $16.41 | 2024 | Zeposia |
| Amgen INC. | $13.85 | 2025 | Uplizna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.